RD-13

N/A

Report date: 2026/01/28 17:56:36

Base Information

Drug NameRD-13
Drug Alias Nameuniversal chimeric antigen receptor T cells (UCAR-T) targeting CD7RD13-02RD 13 02RD-13RD-13-01 +[7] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Universal CAR-TCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell antigen CD7 inhibitors
TargetsT-cell antigen CD7
Therapy Area/IndicationsDiabetes Mellitus, Type 1Anemia, AplasticHematologic Diseases +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing Bioheng Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBioheng Therapeutics US LlcNanjing Bioheng Biotech Co LtdInstitute Of Hematology & Blood Diseases Hospital
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1Anemia, AplasticHematologic Diseases +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A